AZD-2461 is a chemical compound that belongs to the class of small molecules, specifically designed as a potent and selective inhibitor of the enzyme poly(ADP-ribose) polymerase (PARP). This compound has garnered attention in the field of cancer research, particularly for its potential therapeutic applications in treating tumors with deficiencies in DNA repair mechanisms, such as those with BRCA mutations. AZD-2461 is characterized by its ability to enhance the efficacy of DNA-damaging agents, thereby promoting cancer cell death. The compound exhibits favorable pharmacokinetic properties, including good oral bioavailability and a manageable safety profile in preclinical studies. Its mechanism of action involves the inhibition of PARP, which plays a crucial role in the repair of single-strand breaks in DNA. By blocking this repair pathway, AZD-2461 can sensitize cancer cells to chemotherapy and radiation therapy, making it a promising candidate for combination therapies in oncology. Ongoing clinical trials continue to evaluate its effectiveness and safety in various cancer types.

AZD-2461

1174043-16-3: AZD-2461 is a chemical compound that belongs to the class of small molecules, specifically designed as a potent and selective inhibitor of the enzyme poly(ADP-ribose) polymerase (PARP). This compound has garnered attention in the field of cancer research, particularly for its potential therapeutic applications in treating tumors with deficiencies in DNA repair mechanisms, such as those with BRCA mutations. AZD-2461 is characterized by its ability to enhance the efficacy of DNA-damaging agents, thereby promoting cancer cell death. The compound exhibits favorable pharmacokinetic properties, including good oral bioavailability and a manageable safety profile in preclinical studies. Its mechanism of action involves the inhibition of PARP, which plays a crucial role in the repair of single-strand breaks in DNA. By blocking this repair pathway, AZD-2461 can sensitize cancer cells to chemotherapy and radiation therapy, making it a promising candidate for combination therapies in oncology. Ongoing clinical trials continue to evaluate its effectiveness and safety in various cancer types.

CAS 1174043-16-3

AZD-2461

AZD2461

Ref: IN-DA008TDQ

AZD-2461

Ref: 54-BUP09685

AZD-2461

Ref: TM-T2484